Treatment-related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
© 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association..
Introduction: The efficacy of olaparib for treatment-related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment-related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1-year efficacy.
Case presentation: A 75-year-old man initially diagnosed with prostate adenocarcinoma developed treatment-related neuroendocrine prostate cancer after 10-year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a BRCA2 gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects.
Conclusion: Olaparib may be the treatment of choice for treatment-related neuroendocrine prostate cancer in patients with BRCA mutations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
IJU case reports - 7(2024), 2 vom: 28. März, Seite 115-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ikeda, Riko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRCA2 |
|---|
| Anmerkungen: |
Date Revised 06.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/iju5.12679 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369305752 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369305752 | ||
| 003 | DE-627 | ||
| 005 | 20240306233340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/iju5.12679 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM369305752 | ||
| 035 | |a (NLM)38440716 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ikeda, Riko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment-related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. | ||
| 520 | |a Introduction: The efficacy of olaparib for treatment-related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment-related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1-year efficacy | ||
| 520 | |a Case presentation: A 75-year-old man initially diagnosed with prostate adenocarcinoma developed treatment-related neuroendocrine prostate cancer after 10-year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a BRCA2 gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects | ||
| 520 | |a Conclusion: Olaparib may be the treatment of choice for treatment-related neuroendocrine prostate cancer in patients with BRCA mutations | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a BRCA2 | |
| 650 | 4 | |a castration‐resistant | |
| 650 | 4 | |a neuroendocrine tumor | |
| 650 | 4 | |a poly(ADP‐ribose) polymerase inhibitors | |
| 650 | 4 | |a prostate cancer | |
| 700 | 1 | |a Matsuoka, Yoh |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Masaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Ayataka |e verfasserin |4 aut | |
| 700 | 1 | |a Akagi, Kiwamu |e verfasserin |4 aut | |
| 700 | 1 | |a Kageyama, Yukio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t IJU case reports |d 2018 |g 7(2024), 2 vom: 28. März, Seite 115-119 |w (DE-627)NLM313187118 |x 2577-171X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g number:2 |g day:28 |g month:03 |g pages:115-119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/iju5.12679 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |e 2 |b 28 |c 03 |h 115-119 | ||